Maxcyte (MXCT) Non-Current Deffered Revenue (2021 - 2022)
Maxcyte's (MXCT) quarterly Non-Current Deffered Revenue came in at $344600.0 in Q3 2022, down 23.46% quarter-over-quarter from $450200.0 in Q4 2021.
Powered by 
Analysis
Maxcyte (MXCT) Non-Current Deffered Revenue (2021 - 2022) Analysis & Trends
Maxcyte (MXCT) has reported Non-Current Deffered Revenue for 2 consecutive years, with $344600.0 the latest figure, recorded in Q3 2022.
- On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $344600.0 in Q3 2022; TTM through Sep 2022 was $344600.0, a N/A change from a year earlier, with the FY2021 full-year figure at $450200.0, changed N/A from the prior year.
- Non-Current Deffered Revenue was $344600.0 for Q3 2022 at Maxcyte, down from $450200.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $450200.0 in Q4 2021 and troughed at $344600.0 in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 225.64 Bn | 221.57 Bn | 8.34 Bn | - |
| 2 | Danaher | 144.47 Bn | 140.12 Bn | 3.61 Bn | - |
| 3 | Agilent Technologies | 40.90 Bn | 39.15 Bn | 1.04 Bn | - |
| 4 | Illumina | 30.90 Bn | 29.73 Bn | 770.00 Mn | - |
| 5 | Revvity | 13.85 Bn | 12.82 Bn | 416.87 Mn | - |
| 6 | Bio-Techne | 11.27 Bn | 11.00 Bn | 211.39 Mn | - |
| 7 | Bio-Rad Laboratories | 10.12 Bn | 8.50 Bn | 345.80 Mn | - |
| 8 | Repligen | 9.28 Bn | 8.27 Bn | 110.04 Mn | - |
| 9 | 10x Genomics | 8.70 Bn | 8.14 Bn | 112.50 Mn | 9.68 Mn |
| 10 | Maxcyte | 131.93 Mn | 131.93 Mn | 5.60 Mn | - |